Navigation Links
New Chemo Drug May Benefit Some Breast Cancer Patients
Date:3/2/2011

WEDNESDAY, March 2 (HealthDay News) -- The new chemotherapy drug eribulin extends the lives of metastatic breast cancer patients who have received extensive treatment, according to a new study.

The researchers found that among patients whose cancer had spread, those who took the drug lived a median of 2.5 months longer than those who received a physician-chosen treatment -- 13.1 months versus 10.6 months.

The study included 508 women who were given eribulin and 254 women who received treatment of the physician's choice, which was defined as: any single-agent chemotherapy, hormonal or biological treatment approved for cancer treatment; radiotherapy; or symptomatic treatment alone.

The most common side effects in both groups were fatigue and depletion of white blood cells. Numbness and pain stemming from nerve damage were the most common adverse event connected to eribulin that led women to drop out of the study (24, or 5 percent).

The study, known as the EMBRACE trial, was funded by Eisai Inc., which markets eribulin. Dr. Javier Cortes, of the Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology in Barcelona, Spain, and colleagues published the findings in the March 3 online edition of The Lancet.

"This global phase 3 study establishes a potential new standard treatment for women with heavily pretreated metastatic breast cancer, for whom there was previously no chemotherapy treatment with proven survival benefit," the authors wrote.

In a related editorial, Drs. Nancy U. Lin and Harold J. Burstein, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston, said: "EMBRACE provides much needed, high-level evidence for chemotherapy use in patients with heavily pretreated breast cancer. And that evidence suggests that the methods to treat advanced breast cancer are growing, the treatment challenge in refractory disease is a little bit less daunting, and the treatment results are a little bit better than they were before."

Commenting on the study, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, "The findings of this trial are exciting because they will propel eribulin into wider use. This drug shows much promise, and it should certainly be included in additional trials to fully establish its benefit."

"It would be interesting to see if the drug offers the same benefit in women that have not been treated with multiple drugs before exposure to eribulin," she added.

More information

The Metastatic Breast Cancer Network has more about metastatic breast cancer.

-- Robert Preidt

SOURCE: Stephanie Bernik, M.D., F.A.C.S., chief of surgical oncology at Lenox Hill Hospital, New York City, N.Y.; The Lancet, news release, March 2, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. BUSM study shows chemoradiotherapy prior to surgery improves survival
2. Fish oil fights weight loss due to chemotherapy
3. Pot Ingredient May Restore Appetite After Chemo
4. Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients
5. Stray Breast Tumor Cells in Early Chemo Could Be Bad Sign
6. Phase III efficacy data on bevacizumab plus chemotherapy in early breast cancer to be presented
7. Adding ipilimumab to standard chemotherapy treatment for late-stage lung cancer may improve survival
8. Surgery complications linked to chemotherapy delay, U-M study finds
9. Breast cancer: Reducing the risk of unnecessary chemo
10. Combining radiation therapy, chemotherapy safely treats head and neck cancer patients
11. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Chemo Drug May Benefit Some Breast Cancer Patients
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a ... health care, have expanded their existing home health joint venture through an agreement, ... been operating a joint venture home health company with Asante, delivering clinically integrated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. Parsa ... contributed a medical article to the newly revamped Cosmetic Town journal ... the hair transplant procedure known as Follicular Unit Extraction (FUE). , ...
Breaking Medicine News(10 mins):
(Date:10/5/2017)... Ill. , Oct. 5, 2017  In ... Association of Oral and Maxillofacial Surgeons (AAOMS) released ... opioids – to be used as a first-line ... pain. Recognizing ... the AAOMS White Paper "Opioid Prescribing: Acute and ...
(Date:10/2/2017)... -- Eli Lilly and Company (NYSE: LLY ) ... of 2017 on Tuesday, October 24, 2017. Lilly will ... the investment community and media to further detail the ... begin at 9 a.m. Eastern time. Investors, media and ... the conference call through a link that will be ...
(Date:9/28/2017)... 28, 2017 Cohen Veterans Bioscience and Early ... of wearable and home sensors for real-time monitoring of ... Foundation, a nonprofit organization focused on disruptive health solutions ... affordable analytical system to record and integrate behavioral, cognitive, ... ...
Breaking Medicine Technology: